This classification includes CSM1, microsatellite instability (MSI) and immune (14%); CSM2, canonical (37%); CSM3, metabolic (13%); and CSM4, mesenchymal (23%); 13% of cancers could not be classified into any of these groups and may represent a transition phenotype. Here, DES is linked to cancer.